If the latest neurosteroid fails against Huntington's, it's going lower than that and the company's future is very much in doubt. Central nervous system drug development is definitely for the brave.

Central Nervous System (CNS) therapies have significantly progressed in the last decade, propelled by emerging treatment modalities including gene therapies. Neurological indications remain amongst ...

This not only makes eradication of the virus very difficult but also increases the risk of viral mutation, leading to drug resistance and treatment failure. One of these sites is the CNS.

Blue Oak has been operating largely under the radar since it was set up in 2016, but has quietly started building alliances as it prepares to advance new drug classes for central nervous system ...

The two companies will work together on the development of a “next-generation” of psychiatric medicines, although – for now – the drugs themselves and the target indications are being kept ...

Nuvalent, Inc. has promising drugs, zidesamtinib and NVL-655, targeting NSCLC with encouraging data. Read why NUVL stock is a ...

Many medications and drugs have names ending in "ine" or "is". In reality, this observation is based on naming conventions in ...

Vice President, Neuroscience, Genentech, South San Francisco, California, USA. Morgan Sheng started at Genentech in September 2008, having previously spent 14 years as a faculty member in the ...

The blood–brain barrier (BBB) selectively regulates the passage of chemical compounds into and out of the central nervous system (CNS). As such, understanding the permeability of drug molecules ...

Readers hoping to buy Cohen & Steers, Inc. ( NYSE:CNS ) for its dividend will need to make their move shortly, as the... Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under ...

After hours: December 10 at 4:02:46 PM EST ...